Depression – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Depression – Pipeline Review, H2 2019’, provides an overview of the Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Depression

– The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Depression therapeutics and enlists all their major and minor projects

– The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Depression”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Depression

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Acadia Pharmaceuticals Inc

Adamed Sp zoo

Addex Therapeutics Ltd

Aequus Pharmaceuticals Inc

Aision Biotechnologies Inc

Alkermes Plc

Allergan Plc

Amorsa Therapeutics Inc

Anavex Life Sciences Corp

Angelini Group

Antheia Inc

Asulon Therapeutics Inc

Atai Life Sciences AG

Avanir Pharmaceuticals Inc

Avicanna Inc

Axsome Therapeutics Inc

Azevan Pharmaceuticals Inc

Beloteca Inc

Bionomics Ltd

BioStem Technologies Inc

BioXcel Therapeutics Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Calico LLC

Celgene Corp

Cellix Bio Pvt Ltd

Celon Pharma SA

Cerecor Inc

CGeneTech (Suzhou China) Co Ltd

Chase Therapeutics Corp

Clera Inc

Clexio Biosciences Ltd

Compass Pathways Ltd

CSPC Pharmaceutical Group Ltd

CuroNZ Ltd

Delpor Inc

Denovo Biopharma LLC

Douglas Pharmaceuticals Ltd

Dracen Pharmaceuticals Inc

Eisai Co Ltd

Eli Lilly and Co

Evecxia Inc

Evotec SE

Fabre-Kramer Pharmaceuticals Inc

GlaxoSmithKline Plc

GliaCure Inc

GNT Pharma Co Ltd

Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd

H. Lundbeck AS

HEC Pharm Co Ltd

HolsboerMaschmeyer NeuroChemie GmbH

Hua Medicine Shanghai Ltd

Iltoo Pharma

Impel NeuroPharma Inc

Initiator Pharma AS

Intas Pharmaceuticals Ltd

IntelGenx Corp

Intra-Cellular Therapies Inc

INVENT Pharmaceuticals Inc

iX Biopharma Ltd

Jiangsu Gibel Pharmaceutical Co Ltd

Jiangsu Nhwa Pharmaceutical Corp Ltd

Jina Pharmaceuticals Inc

Johnson & Johnson

Kamat Pharmatech LLC

KemPharm Inc

Kissei Pharmaceutical Co Ltd

Krenitsky Pharmaceuticals Inc

Kures Inc

Lactocore

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lixte Biotechnology Holdings Inc

Luye Pharma Group Ltd

Lyndra Inc

Mapi Pharma Ltd

Mapreg SAS

Marinus Pharmaceuticals Inc

MedinCell SA

Medlab Clinical Ltd

MElkin Pharmaceuticals

Mental-Heal Ltd

Meta-IQ ApS

Methylation Sciences Inc

miCure Therapeutics Ltd

Mitsubishi Tanabe Pharma Corp

Navitor Pharmaceuticals Inc

Neurocrine Biosciences Inc

Neurocyte Therapeutics Inc

Neurolixis Inc

NeuroNascent Inc

NeuroRx Inc

Neurotrope Bioscience Inc

Nippon Chemiphar Co Ltd

Novartis AG

Nubiyota LLC

Omeros Corp

Orbis Biosciences Inc

Orexigen Therapeutics Inc

Otsuka Holdings Co Ltd

Overseas Pharmaceuticals Ltd

Pfizer Inc

PharmaMax Corp

Pharmnovo AB

PharmoRx Therapeutics Inc

Phenoquest AG

Phytecs

PNB Vesper Life Science Pvt Ltd

Praxis Precision Medicines Australia Pty Ltd

Primetime Life Sciences LLC

Protagenic Therapeutics Inc

Prous Institute for Biomedical Research SA

Psy Therapeutics Inc

Relmada Therapeutics Inc

Repurposed Therapeutics Inc

Reviva Pharmaceuticals Inc

Richter Gedeon Nyrt

Sage Therapeutics Inc

Saniona AB

Seelos Therapeutics, Inc.

Seneca Biopharma Inc

Shanghai SIMR Biotech Co Ltd

Shanghai Synergy Pharmaceutical Sciences Co Ltd

Shenox Pharmaceuticals LLC

Siragen Pharmaceuticals Inc

SK Biopharmaceuticals Co Ltd

Small Pharma Ltd

Sosei Heptares

Sound Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Sunovion Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Suven Life Sciences Ltd

SyneuRx International Corp

Syntropharma Ltd

Taisho Pharmaceutical Holdings Co Ltd

Takeda Pharmaceutical Co Ltd

Techfields Pharma Co Ltd

Terran Biosciences Inc

Trevena Inc

VistaGen Therapeutics Inc

WhanIn Pharmaceutical Co Ltd

XW Laboratories Inc

Yantai YenePharma Co Ltd

Yungjin Pharm Co Ltd

Zhejiang Jinhua Conba Bio-pharm Co Ltd

Zysis Ltd”

Table of Contents

Table of Contents

Introduction

Depression - Overview

Depression - Therapeutics Development

Depression - Therapeutics Assessment

Depression - Companies Involved in Therapeutics Development

Depression - Drug Profiles

Depression - Dormant Projects

Depression - Discontinued Products

Depression - Product Development Milestones

Appendix

List of Tables

“List of Tables

Table 1: Number of Products under Development for Depression, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 8: Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 9: Number of Products under Development by Universities/Institutes, H2 2019

Table 10: Products under Development by Companies, H2 2019

Table 11: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 12: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 13: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 14: Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 15: Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 16: Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 17: Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Table 18: Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Table 19: Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Table 20: Products under Development by Companies, H2 2019 (Contd..10), H2 2019

Table 21: Products under Development by Companies, H2 2019 (Contd..11), H2 2019

Table 22: Products under Development by Companies, H2 2019 (Contd..12), H2 2019

Table 23: Products under Development by Universities/Institutes, H2 2019

Table 24: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Table 25: Number of Products by Stage and Target, H2 2019

Table 26: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Table 27: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Table 28: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Table 29: Number of Products by Stage and Mechanism of Action, H2 2019

Table 30: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Table 31: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Table 32: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Table 33: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019

Table 34: Number of Products by Stage and Route of Administration, H2 2019

Table 35: Number of Products by Stage and Molecule Type, H2 2019

Table 36: Depression – Pipeline by Acadia Pharmaceuticals Inc, H2 2019

Table 37: Depression – Pipeline by Adamed Sp zoo, H2 2019

Table 38: Depression – Pipeline by Addex Therapeutics Ltd, H2 2019

Table 39: Depression – Pipeline by Aequus Pharmaceuticals Inc, H2 2019

Table 40: Depression – Pipeline by Aision Biotechnologies Inc, H2 2019

Table 41: Depression – Pipeline by Alkermes Plc, H2 2019

Table 42: Depression – Pipeline by Allergan Plc, H2 2019

Table 43: Depression – Pipeline by Amorsa Therapeutics Inc, H2 2019

Table 44: Depression – Pipeline by Anavex Life Sciences Corp, H2 2019

Table 45: Depression – Pipeline by Angelini Group, H2 2019

Table 46: Depression – Pipeline by Antheia Inc, H2 2019

Table 47: Depression – Pipeline by Asulon Therapeutics Inc, H2 2019

Table 48: Depression – Pipeline by Atai Life Sciences AG, H2 2019

Table 49: Depression – Pipeline by Avanir Pharmaceuticals Inc, H2 2019

Table 50: Depression – Pipeline by Avicanna Inc, H2 2019

Table 51: Depression – Pipeline by Axsome Therapeutics Inc, H2 2019

Table 52: Depression – Pipeline by Azevan Pharmaceuticals Inc, H2 2019

Table 53: Depression – Pipeline by Beloteca Inc, H2 2019

Table 54: Depression – Pipeline by Bionomics Ltd, H2 2019

Table 55: Depression – Pipeline by BioStem Technologies Inc, H2 2019

Table 56: Depression – Pipeline by BioXcel Therapeutics Inc, H2 2019

Table 57: Depression – Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Table 58: Depression – Pipeline by Bristol-Myers Squibb Co, H2 2019

Table 59: Depression – Pipeline by Calico LLC, H2 2019

Table 60: Depression – Pipeline by Celgene Corp, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Depression, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports